Pfizer ends hand/penis drug deal, as Auxilium seeks new US indication
This article was originally published in Scrip
Executive Summary
Shares of Auxilium continued their decline on 8 November after falling more than 10% a day earlier following the company’s revelation its partner Pfizer was pulling out of its European and Asian development and commercialization deal for Xiapex (collagenase clostridium histolyticum), sold in the US as Xiaflex.